News | June 02, 2008

First GE Discovery VCT PET/CT Installed in Children's Hospital

June 3, 2008 - Seattle Children's Hospital is the first pediatric facility to install a 64-slice GE Discovery VCT PET/CT, combining the system with tailored pediatric imaging protocols to allow Children�s radiologists to best meet the needs of its pediatric patients by more accurately diagnosing conditions and pinpointing treatment areas, while protecting children from excessive diagnostic radiation exposure.

The Discovery VCT PET/CT scanner pairs Positron Emission Tomography (PET) with Computed Tomography (CT) and takes 64 pictures of the tumor site that are combined into a comprehensive 3D image allowing radiologists to determine the presence of disease, pinpoint specific biopsy sites and accurately monitor the effects of treatment.

The Discovery VCT PET/CT is most commonly used in oncology to diagnose lymphoma, neuroblastoma, brain tumors, sarcomas and thyroid cancer. Additionally, it can also assist in the diagnosis of myocardial viability, ischemia, coronary artery disease and in localizing epilepsy and seizure origin.

Diagnostic imaging with a PET/CT scanner requires a small amount of radiation. Studies have shown that these small amounts of radiation can slightly increase the risk of adverse health effects. At Seattle Children�s Hospital, PET/CT scans are designed to minimize diagnostic radiation while ensuring image quality. The scans are only performed when the benefit far outweighs the risk of adverse effects.

The PET scan is a metabolic imaging technology that detects changes in cell energy to establish whether tumors are active or inactive. The PET scan also determines if tumors have spread locally, or to outlying locations away from the primary tumor. The CT scan is then used to precisely identify the location of these cells within the childn's body.

For more information:,

Related Content

SNMMI Publishes New FDG PET/CT Appropriate Use Criteria
News | PET-CT | October 25, 2017
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has published appropriate use criteria (AUC) for FDG PET/...
Majority of Recurrent Prostate Cancer Patients' Treatment Plan Changed Following Fluciclovine 18F PET/CT
News | Prostate Cancer | October 04, 2017
Blue Earth Diagnostics recently announced the results of a pre-planned interim analysis from an investigational...
Toshiba Highlights Latest CT Advancements at RSNA 2017
News | Computed Tomography (CT) | September 18, 2017
Toshiba Medical announced that it will display several new enhancements to its existing computed tomography (CT)...
Double Targeting Ligands to Identify and Treat Prostate Cancer

The mice were imaged with small-animal PET/CT using 124I-RPS-027 (7.4 MBq [200 μCi]). Credit: JM Kelly et al., Department of Radiology, Weill Cornell Medicine, New York, NY

News | Prostate Cancer | September 14, 2017
Researchers have demonstrated a new, effective way to precisely identify and localize prostate cancer tumors while...
Blue Earth Diagnostics Announcing Results of FALCON PET/CT Trial at ASTRO 2017
News | PET-CT | September 13, 2017
September 13, 2017 — Blue Earth Diagnostics announced the upcoming oral presentation of initial results from the FALC
FDG-PET/CT Predicts Melanoma Patients' Response to Immune Checkpoint Inhibitor Therapy
News | PET-CT | September 07, 2017
September 7, 2017 — Advanced melanoma has a poor prognosis, but immune checkpoint inhibitor therapy can be effective
Videos | Nuclear Imaging | August 24, 2017
Prem Soman, M.D., director of nuclear cardiology at the Heart and Vascular Institute, University of Pittsburgh, and p
ASNC and SNMMI Release Joint Document on Diagnosis, Treatment of Cardiac Sarcoidosis
News | Cardiac Imaging | August 18, 2017
August 18, 2017 — The American Society of Nuclear Cardiology (ASNC) has released a joint expert consensus document wi
PET/CT Tracer Identifies Vulnerable Lesions in Non-Small Cell Lung Cancer Patients

Example of a patient with an upper left lung NSCLC: A: FDG; B: FDG PET/CT; C: Planning radiotherapy based on FDG (66Gy) with BTVm (GTV), CTV and PTV; D: PET FMISO E: FMISO PET/CT; F: boost based on the FMISO PET (76Gy) with BTVh (biological hypoxic target volume) and PTV boost. Credit: QuantIF – LITIS EA 4108 – FR CNRS 3638, Henri Becquerel Cancer Center, Rouen, France

News | PET-CT | July 14, 2017
July 14, 2017 — Fluorine-18 (18F)-fluoromisonidazole (FMISO) is a positron emission tomography (PET)...
Overlay Init